Copenhagen-based Lundbeck Inc. recently suffered a setback in its Phase III DAYBREAK trial of Lu AF35700 for treatment-resistant schizophrenia.
The novel antipsychotic didn’t show statistical superiority versus conventional therapy on the primary endpoint (change in Total PANSS from randomization to week 10), with the announcement leaving investors worried about the Danish company's pipeline
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?